Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

In a further bid to expand its already lucrative portfolio of metabolic and obesity medicines, Denmark’s Novo Nordisk (NOV: N ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...